Results 21 to 30 of about 76,682 (163)
Warfarin is the most commonly used oral anticoagulant in the UK. It is associated with few side effects apart from haemorrhage. The most appropriate way to reverse the anticoagulant effect of warfarin depends on the clinical circumstances. In serious bleeding, rapid reversal is required, whereas in minor bleeding or asymptomatic over anticoagulation, a
openaire +2 more sources
Warfarin remains the most prescribed oral anticoagulant of choice in atrial fibrillation (AF) patient in resource-limited settings. Despite evidence linking Time in Therapeutic Range (TTR) to patient outcomes, its use in clinical practice is not ...
Paisit Kosum +8 more
doaj +1 more source
Spontaneous abdominal hemorrhage due to warfarin treatment
Warfarin is an anticoagulant used in the prevention of thromboembolism. Common clinical indications for warfarin use are atrial fibrillation, artificial heart valves, deep venous thrombosis. Common side effect of warfarin is hemorrhage.
Mustafa Volkan Demir +3 more
doaj +1 more source
BackgroundDespite the proven efficacy of warfarin, its use in patients with Atrial Fibrillation (AF) is reportedly low. We investigated the underuse and overuse of warfarin in the management of AF in general practices in the United Kingdom (UK) against ...
Mohammed A Mohammed +4 more
doaj +1 more source
EFFECTS OF DIFFERENT WARFARIN DOSES ON IL-6 AND COX-2 LEVELS
Background: Warfarin has been widely used for a long time as an oral anticoagulant agent. Warfarin is reported to have inflammatory role as well. The dose of Warfarin plays an important role in up and down regulation of interacting cytokines such as IL ...
Huma Shafiq, Amir Rashid, Asifa Majeed
doaj +2 more sources
Current strategies of anticoagulation therapy for patients with non-valvular atrial fibrillation
Cardioembolic stroke accounts for 20–30% of acute brain infarctions in Japan. This condition is often severe and has poor outcomes. Non-valvular atrial fibrillation (NVAF) is the most common cardiac source of emboli in cardioembolic stroke ...
Masahiro Yasaka
doaj +1 more source
Warfarin Sodium Stability in Oral Formulations
Warfarin sodium is a low-dose pharmaceutical blood thinner that exists in two forms: the clathrate form and the amorphous form. In commercially available warfarin sodium oral suspension, the active pharmaceutical ingredient (API) is added in the ...
Evangelia Dimitrokalli +5 more
doaj +1 more source
Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
Background: Pharmacokinetics of warfarin has not been described in our population. We derived the pharmacokinetic parameters from a validated pharmacokinetic-pharmacodynamic model. Methods: Patients receiving warfarin for at least 6 months were recruited
Kannan Sridharan +2 more
doaj +1 more source
Background The polymorphisms of VKORC1 and CYP2C9 play increasingly important roles in the inter-individual variability in warfarin dose. This study aimed to evaluate the feasibility of clinical application of pharmacogenetic-based warfarin-dosing ...
MingSong Wang, XiLong Lang, ShiTao Cui, Ke Fei, LiangJian Zou, Jia Cao, LiangXu Wang, ShengHui Zhang, XinTian Wu, YiLing Wang, Qiang Ji
doaj
Warfarin Resisance and Recurrent Thrombosis in an Iranian Patient
Warfarin resisance was known as subtherapeutic INR (International Normalized Ratio) in spite of normally prescribed doses of warfarin. There are few reports of warfarin resisance from Iran.
Masuod Malekzadeh, Marzieh Pazoki
doaj

